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Abstract. SMT solvers can be used efficiently to search for optimal
paths across multiple graphs when optimising for certain resources. In the
medical context, these graphs can represent treatment plans for chronic
conditions where the optimal paths across all plans under consideration
are the ones which minimize adverse drug interactions. The SMT solvers,
however, work as a black-box model and there is a need to justify the
optimal plans in a human-friendly way. We aim to fulfill this need by
proposing explanatory dialogue protocols based on computational argu-
mentation to increase the understanding and trust of humans interacting
with the system. The protocols provide supporting reasons for nodes in
a path and also allow counter reasons for the nodes not in the graph,
highlighting any potential adverse interactions during the dialogue.
Keywords: Explanations · Dialogues Games · Argumentation · SMT
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1 Introduction
Intelligent systems are becoming increasingly popular in today’s digital world
with the pervasiveness of Artificial Intelligence (AI). The focus on human-friendly
integration of AI has increased in recent years with growing awareness of the need
for transparency and justifiability of the black-box recommendations made by
some of these systems. Limited transparency and justifiability has been shown
to hamper the mainstream adoption of these systems [2].
An even more urgent need for clarity comes with critical systems, such as clin-
ical decision support systems, and there are ongoing efforts towards eXplainable
Artificial Intelligence (XAI) [2], specially for medical XAI [23]. While most of the
existing approaches to XAI focus on interpretability of machine learning models
[1], rule-based approaches can be used to justify decisions of non-interpretable
systems by explaining why a decision is a good one rather than how it was made.
We follow the later approach here.
? This research was conducted whilst the first author was visiting the University of St
Andrews.
Medical treatment plans (aka clinical guidelines) are drawn from evidence-
based recommendations, and published in the UK by the National Institute for
Health and Care Excellence (NICE)1 to document treatment practices for spe-
cific chronic diseases such as diabetes, hypertension, and so on. The plans capture
a series of steps in the management of the disease, giving an indication of which
advice to follow including which drugs (e.g., from a group) to prescribe at a
given stage of the disease and what changes to do once the disease progresses
(e.g., add a specific medication). These plans, however, fall short for patients
with multiple chronic health conditions, known as multimorbidity, and in par-
ticular they do not account for the potential adverse drug reactions (ADRs)
caused by drugs taken for different conditions [14]. Treatment plans for individ-
ual chronic conditions can essentially be regarded as graphs, and in the presence
of multimorbidities we are in effect trying to search for the optimal path across
several graphs which minimises ADRs as much as possible. Satisfiability Mod-
ulo Theories (SMT) solvers are popular in analysis and model checking settings
because of their expressive power, arithmetic capabilities and scalability [19].
SMT solvers have been used efficiently to identify and minimise ADRs in [5–7].
There is, however, still a need to add clarity to the identified optimal path and
justify why one combination of paths across different treatment plans may be
preferable to another.
The use of computational argumentation has been popular in healthcare [4,
15] and more recently for managing multimorbidity [9, 20], because its formula-
tion and evaluation of pros and cons can be seen as emulating human critical
thinking. Recently argumentation has also generated interest for its explainabil-
ity potential [12, 13] because of its reasoning transparency. Artificial dialogue
based on argumentation allows agents to engage in a gradual exploration of
reasons for a conclusion and potential disagreement. In human argumentation,
argumentation-based dialogue has shown to be effective in improving under-
standing of scientific topics [10]. Consequently we think argumentation is a great
fit for tackling the problem of justifying optimal paths for multimorbidity treat-
ment plans in a way that ensures human engagement.
The contribution of this paper is a novel approach for justifying recommen-
dations of an SMT solver in an interactive way through argumentation-based
dialogues. We use argumentation to augment these recommendations with ex-
planations and propose a novel model of explanatory dialogue protocols to allow
human-like engagement with the explanation model. The explanations model the
underlying reasoning of the SMT solver while the dialogue protocols highlight
any unresolved issues in the recommended solution.
The remaining paper is organised as follows. Section 2 summarises the back-
ground of the argumentation model underlying the explanation dialogues. Sec-
tion 3 presents the dialogue protocols. Finally, Section 4 concludes and identifies
directions for future research.
1 For details see https://www.nice.org.uk
2 Argumentation for pharmaceutical treatment plans
Here we summarise the background research for the work presented in this paper
and introduce relevant underlying concepts related to argumentation.
2.1 Finding optimal plans with SMT solver
We base our approach on the work of Kovalov and Bowles [16] which identifies
optimal treatment plans for multimorbid patients using the optimising SMT
solver Z3 [18]. The authors manually convert the flowchart representations of
clinical guidelines for treating specific health conditions into a compact graph
which they refer to as a Pharmaceutical Graph (PG). A PG is a directed acyclic
graph where the root node represents the diagnosed disease, and all the other
nodes represent drugs or groups of drugs to be given to a patient. A maximal
path in the graph represents a complete treatment plan.
Kovalov and Bowles [16] first create PGs corresponding to different health
conditions for a hypothetical multimorbid patient and feed them to the SMT
solver to identify the optimal paths for each of the PGs such that adverse drug
reactions across all PGs are minimised. They take three types of ADRs into
account: drug-drug interactions, drug-disease interactions and drug-patient in-
teractions. Z3 is a Boolean satisfiability problem modulo theories (SMT) solver
which finds the optimal assignment given by some objective function [3]. The
objective function used by the authors, called score, is computed as a combina-
tion of medicine efficacy (positive score) and drug interaction conflict (negative
score). More comprehensive extensions that incorporate side-effects, time and
patient preferences have been recently developed in [7]. The approach is scalable
to any number of drug alternatives.
2.2 Modelling Explanations
The resulting maximal path described above is a sequence of drugs or group of
drugs for a specific health condition [16]. While PGs encode a score wrt known
ADRs to extract a most effective solution, when presenting the sequence of treat-
ments to a health professional or to a patient, the reasons for this to be indeed
the most effective solution are not immediately accessible. This means that the
user might have to search for additional information to better understand the
solution provided. To facilitate this process, we design a multi-layer explanation
model in order to have flexible interactions that can adapt to the user’s need for
clarification. We organise the graph into abstraction layers and explicitly mark
the abstractions levels in the graph structure in terms of branches, sub-branches
and nodes. We refer to the resulting graph as PGraph. We define four abstraction
levels for the PGraph and the explanations: Branch, Entity, Drug and Group.
A Branch is a cluster of nodes joined by an initial node and a terminating node
such that initial node has only one incoming edge and the terminating node
has only one outgoing edge. An Entity can be an atomic node representing a
Drug or a composite node representing a group of drugs (Group). A Group is a
Fig. 1. PGraphs for Diabetes and Hypertension.
sub-branch with all member drugs related semantically. A path on a PG maps
directly to a PGraph after accounting for additional marking nodes. An example
PGraph is provided in Fig. 1 where the grey shaded nodes represent a path.
In addition to different levels of explanations, we also require to encode text
that can be presented to a user. We base the explanation texts on the drug
information provided by NICE2 and the intuitions given in NICE pathways
themselves. We manually filter out relevant information from these sources and
organize it into types and levels. Types group the explanations into categories
such as justification for a treatment (IP), using graph structure as a justifica-
tion (PGRAPH), drug-drug conflict (DD), drug-disease conflict (CD) and drug-
patient (CP) conflict, while levels correspond to the abstraction layers in the
PGraph. We code these reasons with symbols Ri.
2.3 Argumentation Framework
In explaining a PGraph, our system should be able to progressively explore the
solution path along PGraph identified by the SMT solver, and provide reasons
2 For details see https://bnf.nice.org.uk/
for a specific choice on request from the user. We also require the system to be
able to provide reasons explaining why another path has not been taken. To this
end, we have chosen to encode PGraphs as argumentation frameworks, another
form of graph, where nodes represent arguments and edges represent conflicts
between arguments, where an evaluation process allows the identification of al-
ternative sets of conflict-free nodes. The requirement for our system is two-fold:
the encoding of the PGraph with additional justifications in a structured logic-
based framework from which we can extract arguments that justify the pathway
chosen by the SMT solver; and the definition of an exploratory dialogue proto-
col to allow human-like engagement with the explanation model. In a separate
line of work, we have formulated a structured argumentation framework that
encodes the reasons directly into the framework and allows us to identify a jus-
tified solution for a treatment plan obtained via the SMT solver. In this paper,
however, our focus is on the dialogue describing this justified solution, therefore
we only present here an abstraction of the arguments that can be formulated
about a PGraph. In order to achieve this, we make use of an abstract argumen-
tation framework (AF) as proposed by Dung [11]. Such a framework is defined
as AF = 〈AR, att〉, where AR is a set of arguments and att represents a binary
relation on AR, i.e., att ⊆ AR×AR.
We use the approach of reformulating preferred semantics as argument la-
bellings by Caminada et al. [8] to generate discussions about acceptable as well as
rejected arguments in explanatory dialogue games. Caminada et al. [8] propose
the following definitions which are useful in this regard.
Definition 1. For a framework AF = 〈AR, att〉:
1. A labelling is a total function, Lab : AR→ {in, out, undec}.
2. Lab is an admissible labelling iff for each A ∈ AR:
(a) if Lab(A) = in then ∀B ∈ AR : (B attA ⊃ Lab(B) = out).
(b) if Lab(A) = out then ∃B ∈ AR : (B attA ∧ Lab(B) = in).
3. Lab is a preferred labelling iff it is an admissible labelling where in(Lab) and
out(Lab) are maximal (w.r.t. set inclusion) among all admissible labellings.
4. A preferred extension is the set of in-labelled arguments of a preferred la-
belling.
Here, we compute preferred extensions as above, and we then use the exten-
sions as the basis of a dialogue game inspired by the approach of Shams et al. [22],
where they use preferred semantics as the basis of a Socratic discussion. We map
the optimal paths returned by the SMT solver to equivalent preferred extensions
and use preferred labelling to generate discussion about in and out status of each
argument representing a node on a specific path.
Internally we model three types of arguments in the AF: path arguments,
explanation arguments, and prescription arguments. We assume that the con-
clusion of a Path argument is a node representing a drug or a graph structure
marker such as a start branch node. An Explain argument for a drug is used
to conclude that there is a justifications for prescribing the drug, and will in-
clude a specific reason Ri. A Prescribe argument concludes that if there is a
justified drug, the drug can be prescribed. Path arguments attack all other Path
and corresponding Prescribe arguments that are not on the same path. A Path
argument can also attack Explain arguments of nodes not in the selected path
if the latter describes an ADR for that particular Path argument. Consequently,
each extension includes arguments prescribing a particular drug on a path in the
graph along with its corresponding explanations.
3 Dialogue Games for Explanations
Formally dialogue games are interactions between two or more players according
to a pre-defined set of rules [17]. The rules describe commencement conditions,
permitted utterances (locutions), permitted combinations of locutions, commit-
ments of participants, and termination conditions for the game. Dialogue game
protocols have been developed for most of the primary dialogue types identified
by Walton and Krabbe [24] such as Information Seeking, Inquiry, Persuasion,
Negotiation, Deliberation and Eristic Dialogue.
We present two explanatory dialogue game protocols based on the Informa-
tion Seeking dialogue which involves one participant seeking an answer from the
other participant, who the former believes knows the answer. The objective of
the dialogue game is to justify why a node is included or not included in a path.
The game has two participants: an Oracle that disseminates information and
a Seeker who is looking for explanations. The Oracle has the AF and the ex-
tension corresponding to the recommendation by the SMT solver as part of
its knowledge base. The Oracle knows the preferred labelling and shares argu-
ments related to the treatment pathway with the Seeker at the start of the game
through a claim. This is a list of Path arguments (labelled Lab(Arg) = in nodes)
along with the Path arguments labelled Lab(Arg) = out; we refer to this set as
S where (Arg,Lab(Arg)) ∈ S if Arg ∈ AR and Lab is a preferred labelling.
Subsequently, the Oracle uses the explanations present in the extension to
answer the questions by the Seeker. In our dialogue protocols, the Seeker corre-
sponds to a Patient agent seeking explanations for recommended medications.
We define two versions of the dialogue protocols, passive explanatory protocol
and active explanatory protocol based on the role of the Seeker. In the former,
the Seeker acts as a passive listener while in the latter, the Seeker plays an active
role in the dialog by confirming or refuting the Oracle’s assumptions about its
preferences. Passive protocol covers the essential interaction and can be used
in a scenario where preference information is missing such as an agent seeking
information on behalf of another. Active protocol, on the other hand, provides
detailed interaction which takes preferences into account and models a real world
medical practice of taking patient history. The subsequent sections formalise the
protocols and provide example dialogues.
Each dialogue protocol has three stages: Commencement, Progress, and Ter-
mination. The protocol specifies what speech acts can be exchanged according
to what was previously exchanged in the dialogue at each phase. In our model,
this is represented with a table where the right-hand side column states what
speech act can be used in response to the speech act moved on the left-hand side
column (see Table 1 and Table3). In the dialogue protocol, participants have a
commitment store CS which includes a set of arguments with which the partici-
pants have committed to stand by [17]. In our dialogue, the commitment store is
formed by arguments exchanged and related attacks. During the dialogue, partic-
ipants update the commitment store via an assertion Assert(Arg) such that the
new commitment store result in CS = CS ∪ Arg, assuming monotonic updates.
If an argument Arg exchanged is a rejection of a previous argument, we assume
that CS is updated with a new attacking argument Arg′ where Arg′ attArg; this
update is referred to as ∼Arg for convenience. We provide example dialogues
in Table 2 and Table 4 with the three dialogue stages marked. The tables show
the locutions underlying each natural language sentence next to each sentence
and highlight the corresponding explanation Types and Levels that the natural
language explanation represents. The last column shows example assertions for
the CS of each participant including the assertion type and argument as defined
in Table 1 and Table 3.
3.1 Passive Explanatory Dialogue Game
In this dialogue, the Seeker plays a passive role and only receives updates from
the Oracle. Information flow is one sided. Fig. 2 shows an overview of the dia-
logue.
Fig. 2. Passive Explanatory Dialogue Overview.
Commencement The first move by Oracle (O) is a Claim which sets the
context of the dialogue.
Progress
1. Every subsequent move by O is an explanation for the previous move of
Seeker (P).
2. Each subsequent move by P is a query about an in or out label in the claim.
3. P can repeat any query until O forces it to move on by sending a Move
locution.
Table 1. Passive Explanatory Dialogue Protocol Definition.
Request Response
StartP ClaimO(S)
ClaimO(S) WhyP (queryi) where queryi ∈ S and query can be in-query or
out-query
WhyP (query) BecauseO(Rij) where Rij represents all the reasons from 1 to
i at abstraction level j. Different reasons at the same level can
be combined using and or alert depending on the context. This
response equals an assertion of one of the types defined as:
Assert(Arg): simple assertion where Arg ∈ AR.
Assert-Alt(Arg): asserting PGRAPH Type reason.
Assert-CD(Arg): asserting a drug-disease conflict as reason.
Assert-DD(Arg): asserting a drug-drug conflict as reason.
WhyP (in-query) AlertO(Rij) where Rij as previously explained. Alert message
indicates a counter reason and represents a conflict that cannot
be helped.
But-WhyP (query) BecauseO(Rij−1) where j−1 is the next lower abstraction level
than was used in previous BecauseO response for same query.
But-WhyP (in-query) AlertO(Rij−1)
But-WhyP (query) MoveO if j − 1 = 0 where j equals the maximum number of
levels defined.
MoveO WhyP (queryk) where queryk 6= queryi for queryk, queryi ∈ S
and queryi has already been dealt with.
BecauseO EndP
AlertO EndP
EndP No response. End dialogue session.
4. O provides all the explanations at the highest abstraction level in the graph
first and moves on to the next lower abstraction level for subsequent repe-
titions of the query until it runs out of explanations. It then uses the Move
locution.
5. O provides supporting reasons (IP Type) to justify an in status or counter
reasons (CD, DD Types) to explain any possible conflicts that influenced the
out label assignment.
Termination
1. P can terminate the dialogue at any time by using an End locution.
2. O can end the dialogue when all the nodes in the claim have been justified.
3.2 An example dialogue
We provide an example of a passive exploratory dialogue in Table 2. Subscripts O
and P represent the Oracle and Seeker respectively and identify the participant
making the move. Assume that the resulting argumentation framework for a path
chosen by the SMT solver on the basis of a PGraph in Figure 1 is presented in
Figure 3.
Fig. 3. Argument Graph for the AF of Table 2.
The AF is represented using an argument graph where the nodes represent ar-
guments and the directed edges point towards the attacked nodes. Let arguments
A1..A8 ∈ AR represent edges in a PGraph, A9..A13 ∈ AR represent correspond-
ing justifications and A14..A17 ∈ AR represent prescriptions for drugs repre-
sented by A5..A8. Arguments {A1, A2, A3, A5, A6, A9, A10, A11, A13, A14, A15}
represent a preferred extension which is part of the preferred labelling.
3.3 Properties of the Protocol
1. The protocol exploits the lack of path order in the extension by allowing P
to query about any random node in the Claim.
2. The protocol preserves the graph abstraction levels qualitatively through
abstractions of explanations.
3. O combines more than one explanations as a justification for the same query
if multiple explanations exist at the same abstraction level.
4. The protocol ensures termination by preventing infinite loops using two
strategies:
(a) O cannot repeat the same answer for the same query, rather it is forced
to exhaust explanations at different abstraction levels progressively.
(b) P cannot repeat any query for which it has received a Move locution.
5. The protocol highlights any inconsistency between nodes in an extension
through explanations by grouping supporting reasons for a node with counter
reasons indicating possible adverse interactions.
Table 2. Passive Explanatory Dialogue example
Dialogue Explanation
Type/Level
Locutions Commitment
Store
Commencement:
O: You have Diabetes
and Hypertension. Let us
go through your recom-
mended NICE pathways
for drug treatment. We
will go through each drug
one by one. Suggested
solution is: S= [Dia-
betes, in(Metformin),
out(Sulfonylurea),
out(Acarbose),
in(Olmesartan) ...]
Claim(S) Assert(Diabetes) As-
sert(Hypertension)
Assert(Metformin)
Assert( Sulfonylurea)
Assert( Acarbose)
Assert(Olmesartan)
...
Progress:
P: Why is Metformin sug-
gested?
Why(in-Metformin)
O: Because it is the de-
fault treatment on the
recommended pathway
Type
IP/Branch
Level
Because Assert(A8)
P: But why is Metformin
suggested?
But-Why(in-
Metformin)
O: Because it is initial
drug for treating Dia-
betes
Type IP/Drug
Level
Because Assert(A9)
P: Why is Sulfonylurea
not suggested?
Why(out-
Sulfonylurea)
O: Because Metformin is
an alternative to Sulfony-
lurea.
PGraph/
PGraph Level
Because Assert-Alt (Met-
formin, Sulfonylurea)
P: But why is Acarbose
not suggested?
But-Why(out-
Acarbose)
O: Because it adversely
reacts with suggested
drug Olmesartan.
Type
DD/Drug
Level
Because Assert-
DD(Acarbose,
Olmesartan)
Termination:
P: I have now received an update on the recommended pathway.End
3.4 Active Explanatory Dialogue Game
In this case the Seeker actively participates in the conversation and confirms
or refutes the assertions of the Oracle. The protocol follows a static update ap-
proach, where Seekers assertions do not take immediate effect. The Oracle passes
the Seekers assertions to the SMT solver to get a more customized recommen-
dation and uses that as the basis of a new discussion. In case Seekers assertions
rule out all possible path options in the graph, the SMT solver returns the path
that optimizes Seekers preferences even if it is not possible to meet all the re-
quirements. Fig. 4 shows a schematic overview of the workflow.
Fig. 4. Active Explanatory Dialogue Overview.
The dialogue starts off with the Oracle going through a checklist of items
with the Seeker which capture Seeker preferences such as patient intolerance of
specific drugs in a medical setting. We modelled the preferences for multimorbid
patients by considering drug information available online and talking to experts.
We learned that the presence of three conditions need to be considered before
prescribing any drug: hepatic impairment, renal impairment, and pregnancy.
This information is not part of the PGraph, rather the Oracle extracts this
information from the Seeker at the start and passes it to the SMT solver which
takes them into account when finding the suitable path.
Commencement
1. The first move by Oracle (O) marks the start of the Checklist phase in which
each subsequent move by O is directed towards establishing preferences of
the Seeker (P).
2. Each move by P in this phase confirms or refutes the assertion made by O
in previous move.
3. O ends Checklist phase by send a Claim locution which proceeds as before.
Table 3. Active Explanatory Dialogue Protocol Definition.
Request Response
ChecklistO Ready-ChecklistP
Assert-ItemO(Argi) Assert-ItemP (Argi) where Argi ∈ AR is
the ith item on the check list and can equal
∼Argi to show rejection of the assumption
by the Seeker.
BecauseO(Rij) with a simple assertion,
AssertO(Arg) as only this assertion type is
defeasible. The rest represent facts which
cannot be disputed by the Seeker.
AssertP (Arg) where Arg ∈ AR. A posi-
tive Arg shows approval by Seeker whereas
∼Arg represents rejection of the recom-
mendation.
AssertP (Arg) ConcedeO
EndP AlternativeO(S)
AlternativeO Ready-AlternativeP
AlternativeO RefuseP
AcceptO(S) ConcedeP (S)
Ready-AlternativeP ClaimO(S)
AcceptO(S) RejectP
RejectP AlternativeO
RefuseP No response. End dialogue.
Progress
1. The progress rules for passive dialogue hold. Additionally each explanation
for a query about an in labelled argument requires P to state its prefer-
ence for the argument Arg ∈ AR mentioned in the explanation by either
confirming or refuting the assumption of O regarding Arg.
2. O can propose an alternative claim after all the labels in the first claim have
been discussed. The dialogue then proceeds with the alternative claim as
before.
Termination
1. P can end the dialogue at any time by using an End locution as before.
2. P accepts the proposed solution.
3. P refuses the offer of O to discuss an alternative claim.
Active Explanatory Dialogue Protocol extends Passive Dialogue Protocol
with additional responses given in Table 3. Table 4 provides an example of how
this dialogue starts.
3.5 Properties of the Protocol
1. O can use the assertions of P regarding its preferences as justifications when
discussing the alternative claim.
Table 4. Active Explanatory Dialogue Game example.
Dialogue Explanation
Type/Level
Locution Commitment
Store
Commencement:
O: Lets go through your
basic health check list.
Checklist
P: OK. I am ready Ready
O: Do you suffer from
Hepatic Impairment?
Type CP/Drug
Level
Assert-Item Assert(C2)
P: No, I do not suf-
fer from Hepatic Impair-
ment.
Assert-Item Assert(∼C2)
O: Do you suffer from Re-
nal Impairment?
Type CP/Drug
Level
Assert-Item Assert(C3)
P: No, I do not suffer
from Renal Impairment.
Assert-Item Assert(∼C3)
2. Since the same query can be repeated, P must repeat the assertions. This
could lead to an inconsistency if P changes the truth value for its assertion.
This can be resolved in two ways:
(a) By preventing P from changing the truth value for the same query.
(b) By allowing P to change truth values and letting the last truth value
hold. This last value can then be passed to the SMT solver.
3. O can use an estimate of how much P’s assertions contradict its world view
and use a threshold value to proceed with finding an alternative claim. O
could resolve minor objections by itself if the estimate is less than the thresh-
old value.
4 Conclusion and Future Work
Explanations are an important tool to increase the trust we have on the recom-
mendations of AI systems. Because of their critical importance, numerous ap-
proaches have been developed for clinical decision support such as expert systems
[21], SMT solvers [5, 6], and argumentation [9, 15]. Here we use argumentation
in an explanatory role to explain the decisions of the SMT solver.
We show how the recommendations of a black-box model like the SMT solver,
can be justified through argumentation-based explanatory dialogue games. We
describe how the dialogue games can provide explanations for the underlying rea-
soning of the SMT solver in calculating optimal paths which minimize ADRs.
We also show that the games protocol is flexible and can highlight possible ADRs
qualitatively. The approach allows engaging with the justifications behind the
recommendations at various abstraction levels, resulting in a dialogue model
which adapts to specific needs of the user. It also allows additional information
such as preferences to be introduced without overwhelming the user. The ar-
gument formulation is very expressive and allows both supporting reasons for
selecting a node to be modelled as well as counter reasons expressed as a negative
relationship between entities. The reasons themselves form part of the premise
of the arguments, and are represented as propositions which are mapped to nat-
ural language representation during the dialogue. This approach can be used for
interactive explanatory dialogues to explain similar sequence graphs in different
domains when the underpinning justification model is provided.
In the future, we plan to divide the Oracle between multiple agent special-
ists as it will enable a more modular approach. Another possible direction is
to explore the changes in the dialogue protocol if the Seeker’s assertions have
immediate effect. The current protocol takes the credibility of the agents for
granted. It will be interesting to see how adding a credibility function can affect
the dependability of the dialogue game. Most importantly, we plan to evaluate
the approach through user studies involving health practitioners and patients
alike and how they engage with our explanatory dialogue games. This will not
only give us a mechanism to validate our approach, but also explore further
arguments such as whether in some cases the optimal solution computed by an
SMT solver is not in fact the preferred one.
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